



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	101.98
Trade Time:	12:53 PM ET Jan 18, 2018
Change:	-0.04 (0.044%)
Day Range	101.56 - 102.86
52-Week Range	94.55 - 147.17
Volume	3,715,109

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 8, 2018 [Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance](#)
- Jan 7, 2018 [Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies](#)
- Jan 3, 2018 [Celgene Corporation to Announce Fourth Quarter and Full-Year 2017 Results on January 25, 2018](#)
- Jan 2, 2018 [Celgene Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)
- Dec 21, 2017 [Celgene and LYSARC Provide Update on Phase III 'RELEVANCE' Study of REVLIMID® in Combination with Rituximab \(R²\) for the Treatment of Previously Untreated Patients with Follicular Lymphoma](#)

Upcoming Events [\[View all \]](#)

Jan 25, 2018 9:00 AM ET [Celgene Corporation Q4 2017 Earnings Conference Call](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

- Feb 10, 2017 [Annual Report \(10-K\)](#)
- Apr 27, 2017 [Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017 [Quarterly Report \(10-Q\)](#)
- Jul 27, 2017 [Quarterly Report \(10-Q\)](#)
- Apr 27, 2017 [Quarterly Report \(10-Q\)](#)